Indian Journal of Pathology and Microbiology
Home About us Instructions Submission Subscribe Advertise Contact e-Alerts Ahead Of Print Login 
Users Online: 1724
Print this page  Email this page Bookmark this page Small font sizeDefault font sizeIncrease font size


 
  Table of Contents    
REVIEW ARTICLE  
Year : 2019  |  Volume : 62  |  Issue : 2  |  Page : 199-205
Small round cell lesions of the bone: Diagnostic approach, differential diagnoses and impact on treatment


1 Department of Surgical Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
2 Department of Pathology, All Indian Institute of Medical Sciences, New Delhi, India
3 Department of Pathology, Regional Cancer Centre, Thiruvananthpuram, Kerala, India

Click here for correspondence address and email

Date of Web Publication10-Apr-2019
 

   Abstract 


Small round cell lesions of the bone encompass a heterogeneous group of tumors and tumor-like lesions, including Ewing sarcoma, small cell osteosarcoma, mesenchymal chondrosarcoma, neuroblastoma, non-Hodgkin's lymphoma (NHL), “Ewing-like” undifferentiated round cell sarcomas, metastasizing small cell carcinoma, along with plasma cell dyscrasia and Langerhan's cell histiocytosis. At the same time, there are tumor mimics, for example, chronic osteomyelitis, which has overlapping radiologic features with Ewing sarcoma and a primary intraosseous NHL. An exact diagnosis necessitates integration of clinical, radiologic, pathologic, and ancillary test results, including immunohistochemical and molecular results. Currently, there are several immunohistochemical markers and specific molecular signatures, driving most of these tumors, available, for an exact diagnosis. This review focuses on a pragmatic approach towards uncovering specific small round cell lesions of the bone, emphasizing upon integration of traditional morphology with ancillary techniques, including immunohistochemical markers and molecular techniques, the latter, especially in cases of Ewing sarcoma, Ewing-like undifferentiated round cell sarcoma, mesenchymal chondrosarcoma, and neuroblastoma. Subsequent to the diagnostic approach, including an impact on treatment, individual intraosseous round cell lesions have been described in detail. The references include updated articles from PUBMED.

Keywords: Ewing sarcoma, immunohistochemistry of round cell sarcomas, intraosseous lymphoma, Langerhans's cell histiocytosis, mesenchymal chondrosarcoma, molecular cytogenetics in bone tumors, neuroblastoma, small round cell lesions of the bone

How to cite this article:
Rekhi B, Mridha A, Kattoor J. Small round cell lesions of the bone: Diagnostic approach, differential diagnoses and impact on treatment. Indian J Pathol Microbiol 2019;62:199-205

How to cite this URL:
Rekhi B, Mridha A, Kattoor J. Small round cell lesions of the bone: Diagnostic approach, differential diagnoses and impact on treatment. Indian J Pathol Microbiol [serial online] 2019 [cited 2019 Apr 24];62:199-205. Available from: http://www.ijpmonline.org/text.asp?2019/62/2/199/255837





   Introduction Top


Primary round cell lesions of the bone constitute a heterogeneous group, including malignant mesenchymal neoplasms and tumor-like lesions, mostly occurring in pediatric patients, including adolescents. These can be clinic-radio-pathologically overlapping, leading to diagnostic challenges in sorting out the individual entities. An exact diagnosis in such cases is extremely important as most of the small round cell tumors (RCTs), although aggressive, are curable with their tailored chemotherapy regimens.[1],[2],[3],[4],[5]

Various RCTs with their specific chemotherapy protocols are as follows:

  1. Ewing sarcoma/primitive neuroectodermal tumor (PNET): This tumor is treated by Ewing family of tumors (EFT) 2001 chemotherapy protocol. These tumors are also radiosensitive.
  2. Undifferentiated “round” cell (“Ewing-like”) sarcoma: These tumors are treated similarly as EFTs. These include a heterogeneous group of genetically defined sarcomas, such as BCOR-CCNB3 and CIC-DUX4-positive sarcomas, characterized by relatively aggressive clinical outcomes, especially the latter subtype.
  3. Mesenchymal chondrosarcomas: These are treated similarly as EFTs; however, they are characterized by relatively aggressive clinical outcomes.
  4. High-grade, small cell osteosarcoma: These are treated by a specific chemotherapy in adjuvant settings, mostly preceding surgical resection. These tumors are not radiosensitive
  5. Neuroblastoma: Treated by children's oncology group (COG) protocol.
  6. Non-hodgkin's lymphomas (NHLs): High-grade, large B-cell (CD20-positive) lymphomas are treated by CHOP-Rituximab (R) (anti-CD20), anaplastic large cell lymphomas (ALCLs) are treated by MCP842 protocol. Radiotherapy is also considered while treating these tumors.
  7. Small cell osteosarcoma. Treated similarly as a conventional osteosarcoma, by OGS 2012 chemotherapy protocol, at Tata Memorial Hospital, Mumbai.[6]
  8. Other entities, such as plasma cell tumors and Langerhans's cell histiocytosis (LCH) constitute as differential diagnoses of the various intraosseous small RCTs.[1],[2],[3],[4],[5],[6]


An ideal approach towards diagnosis and management of these tumors is practising a multidisciplinary approach, which includes integration of clinical, radiologic, and histopathologic findings. Most of these lesions, including tumors occur in pediatric patients.

During the initial diagnostic “work-up” of any intraosseous lesion, a reasonably well-exposed radiologic image, especially a plain X-ray/radiograph is usefulwhile differentiating a Ewing sarcoma from a small cell osteosarcoma. Lytic lesions are noted in LCH, whereas sclerotic, destructive lesions with periosteal reactions are seen in Ewing sarcomas and osteosarcomas, with different types of periosteal reactions, in both these lesions.[4] Computed tomogram (CT) scan and magnetic resonance imaging (MRI) are useful in staging these tumors. Other modalities, such as a metaiodobenzylguanidine (MIBG) scan and other functional imaging are valuable in the diagnosis of a neuroblastoma.[7]

Certain laboratory investigations are equally crucial, such as alkaline phosphatase levels in osteosarcomas, urinary vanillyl mandelic acid (VMA) levels in neuroblastomas, lactate dehydrogenase levels in NHLs, and beta 2 microglobulin levels with serum electrophoresis in cases of plasma cell dyscrasia.[8]

In the present times, where “needle is preceding the scalpel,” efforts should be made for exact categorization of malignant RCTs, either on smears, cell blocks, or histopathology, with immunocyto- or immunohistochemistry (IHC).[9]

Morphology remains the initial point that helps in deciding which immunohistochemical markers or other ancillary tests would be required in diagnosing a particular case. On pathologic examination, malignant round cells are mostly characterized by small, round, relatively undifferentiated appearing nuclei with scant cytoplasm. However, to a morphologist these might appear in one of the two forms as follows:

  1. Small blue round cells: Tumor cells with round cells and scant cytoplasm. For example, Ewing sarcoma, neuroblastoma, etc.
  2. Relatively large, blue to “pink” round cells: Tumor cells with round nuclei and abundant eosinophilic to amphophilic cytoplasm. For example, plasmacytoma/plasma cell dyscrasia, anaplastic large cell lymphoma (ALCL), rhabdomyosarcoma (mostly in soft tissues), etc.


Furthermore, certain morphological features or “clues” such as rosettes in Ewing sarcoma, “salt and pepper-like” chromatin and neuropil in neuroblastomas, plasmacytoid appearance of tumor cells with “cartwheel-like chromatin” in a plasma cell dyscrasia etc., are helpful in formulating morphological differential diagnoses at the upfront.

An exact subtyping of malignant RCTs requires ancillary techniques such as IHC and molecular techniques (reverse transcriptase polymerase chain reaction and/or fluorescence in situ hybridization). The utility of electron microscopy has reduced over the years, in view of cost and logistic reasons.

Optimal panels of various immunohistochemical antibody markers for individual malignant RCTs are as follows:

  • Ewing sarcoma: MIC2/CD99 (invariably diffuse, cytoplasmic membranous immunoexpression), NKX2.2, Fli1, Caveolin, coupled with negative expression of LCA.
  • Neuroblastoma: Synaptophysin, chromogranin, neuron-specific enolase (NSE), and CD56.
  • Non-Hodgkin's lymphomas: LCA, CD20, and other lineage specific markers, such as CD30 for ALCL (ALK+ or ALK-), Tdt for lymphoblastic lymphoma, etc.
  • Small cell osteosarcoma: SATB2. Considering a small cell ostosarcoma can be positive for MIC2, similar to Ewing sarcoma, further molecular testing is recommended as Ewing sarcoma is characterized by a specific underlying translocations t (11; 22) (EWS-FLI1), in most cases.
  • Plasma cell dyscrasia/myeloma: CD138 (Syndecan-1), Kappa, and lambda for evaluating light chain restriction
  • Rhabdomyosarcoma: Desmin, MyoD1, Myogenin
  • Mesenchymal chondrosarcoma: MIC2/CD99 and Leu7. S100 protein highlights the chondroid component.

    It is noteworthy that CD99/MIC2 is also positive in cases of lymphoblastic lymphoma, poorly differentiated synovial sarcoma, mesenchymal chondrosarcoma, and melanoma, to name but a few tumors.[1],[2],[3],[4],[5],[10],[11],[12],[13],[14],[15],[16],[17]

    Individual small round cell lesion/tumor

    Ewing sarcoma

    As per the World Health Organization (WHO) classification of tumors of soft tissue and bone, Ewing sarcoma or Ewing sarcoma family of tumors (ESFTs) are a group of small round cell sarcomas showing varying degree of neuroectodermal differentiation, detected by light microscopy, IHC, and/or by electron microscopy.[15] Microscopically, these tumors display uniform, small round cells with round nuclei, scant cytoplasm, and fine nuclear chromatin. By IHC, most of these tumors display diffuse cytoplasmic membranous immunostaining for CD99/MIC2 and intranuclear staining for Fli1.[11],[15] Both these markers are sensitive, however not specific for diagnosis of a Ewing sarcoma. Lately, NKX2.2 has been idenified as a useful IHC marker for diagnosing Ewing sarcomas. Howver, it has limited specificity.[12]

    Ewing Sarcoma is genetically characterized by recurrent translocations between EWSR1 (Ewing sarcoma RNA binding protein 1) and ETS family of transcription factors. Most of the tumors harbor t (11; 22) – EWSR1-FLI1 or t (21; 22) – EWSR1-ERG transcripts.[17],[18] Detection of these chimeric trascripts and their interpretation in a clinico-radio-pathologic context constitutes as the diagnostic “gold standard” for a Ewing sarcoma.

    In the recent WHO classification of tumors of soft tissue and bone, a new category of sarcomas has been introduced, namely undifferentiated/unclassified round cell sarcomas, characterized by cells with relatively monotonous round to ovoid cytomorphology with high nuclear to cytoplasmic (N: C) ratios, but no distinct line of differentiation. These tumors lack consistent genetic abnormalities, seen in cases of Ewing sarcoma. Clinically, these tumors are usually found in younger patients, at any location, more frequently in somatic soft tissue sites and are characterized by a relatively more frequent rapid growth and a variable response to presently available conventional chemotherapy regimens [Figure 1], [Figure 2], [Figure 3], [Figure 4].[1]
    Figure 1: Ewing sarcoma (a-d). (a) Plain radiograph: diaphyseal, permeative lesion, involving fibula with layered periosteal reaction. (b) Microscopy: malignant small round cells in a diffuse pattern (H and E, ×400). (c) By immunohistochemistry (IHC), tumor cells displaying diffuse, intense cytoplasmic membranous staining for CD99/MIC2 (Diaminobenzidine, ×400). (d) Diffuse intranuclear Fli1 immunoreactivity (Diaminobenzidine, ×400). (e) Focal immunostaining synaptophysin positivity (Diaminobenzidine, ×400)

    Click here to view
    Figure 2: Ewing sarcoma (a and b). (a) Perivascular, rosettoid arrangement of malignant small round cells (H and E, ×400). (b) Diffuse, immunostaining for CD99/MIC2 (Diaminobenzidine, ×400). Case of Ewing sarcoma treated with neoadjuvant chemotherapy (c-e). (c) Pre-treatment microscopic features of Ewing sarcoma (H and E, ×400. (d) Diffuse CD99/MIC2 immunostaining (Diaminobenzidine, ×400). (e) Post-chemotherapy response: hyalinization and scattered inflammatory cells with no residual tumor (H and E, ×200)

    Click here to view
    Figure 3: (a) Case, initially reported as an osteosarcoma (in view of an associated cartilaginous fragment) (H and E, ×200). (b) Post-chemotherapy showing residual tumor cells (H and E, ×200). (c) Microscopic examination of an adrenal lesion, raising suspicion of Ewing sarcoma (H and E, ×400). (d) Tumor cells displaying EWSR1 rearrangement (red green split signals) by fluorescence in-situ hybridization (FISH), confirming a diagnosis of Ewing sarcoma. (DAP1, 1000)

    Click here to view
    Figure 4: (a) Intraosseous tumor, comprising malignant round to polygonal cells with interspersed osteoid, indicative of a small cell osteosarcoma (H and E, ×400). (b) Tumor cells lacking EWSR1 rearrangement (red green fused signals) by FISH, ruling out a Ewing sarcoma (DAP1, 1000)

    Click here to view


    Furthermore, gene expression profiling has unraveled specific transcripts within these undifferentiated, “Ewing-like,” round cell sarcomas, most commonly CIC-DUX4, and BCOR-CCNB3 gene fusions, as recently documented.[13],[14],[19],[20]

    CIC-DUX4-positive tumors mainly affect young adults in the third or fourth decades of life and affect soft tissues more frequently than bones. These tumors represent a clinically aggressive subset of undifferentiated round cell sarcomas.[14],[19],[21] BCOR-CCNB3- positive sarcomas, occurring in extremities, are associated with a relatively favorable clinical course.[13]

    Although a diagnosis of Ewing sarcoma is considered on histology, it should be confirmed by immunohistochemistry and molecular testing, according to the recent European Society of Medical Oncology (ESMO) guidelines.[22],[23]

    Mesenchymal Chondrosarcoma

    Mesenchymal chondrosarcoma is one of the rarest bone sarcomas, histologically characterized by a bimorphic growth pattern consisting of islands of more or less differentiated cartilage, admixed with a small cell malignancy frequently associated with a hemangiopericytomatous pattern. About 1/3 of cases occur in the soft tissues.

    Majority of the cases are reported in the jaw bones, followed by spine, ilium, and ribs. Involvement of skull bones is extremely rare. Among the extra skeletal sites, meninges are reported to be a preferred site of involvement.

    Mesenchymal chondrosarcoma consists of two distinct elements–malignant small round cells and islands of cartilage in varying proportions. The nuclei of small cells are usually round, but may be oval or even spindle shaped. Cytoplasm is scanty and nuclei have usually dense chromatin. One of the characteristic features is thin walled vessels, leading to a hemangiopericytomatous growth pattern.

    Immunohistochemically, S100 protein is positively expressed in chondroid islands and CD99/MIC2 is expressed in the small cells [Figure 5].[24],[25] Sox 9 (transcription factor) has been shown to be helpful in differentiating a mesenchymal chondrosarcoma from other small cell malignancies.[26] An identical Robertsonian translocation involving chromosomes 13 and 21 [der (13; 21) (q10; q10)] was reported in mesenchymal chondrosarcoma.[27] Ten years later, a recurrent HEY1-NCOA2 fusion was identified in mesenchymal chondrosarcomas.[28]
    Figure 5: Plain radiograph pelvis showing a tumor involving pelvic bone and soft tissues (arrow head) with areas of calcification ('ring' and 'arc'). (b) Microscopy: tumor comprising malignant round cells arranged in a hemagiopericytomatous pattern, juxtaposed with cartilaginous component (asterix) (H and E, ×400). (c) Immunohistochemically, tumor cells displaying cytoplasmic positivity for CD99/MIC2 (Diaminobenzidine, ×400). (d) S100 protein distinctly highlighting the chondroid component (Diaminobenzidine, ×400)

    Click here to view


    Some patients present with disseminated metastasis, but others survive for decades. A long term follow-up is mandatory in such cases, since metastasis after 20 years has been reported.[24]

    Neuroblastoma (metastatic)

    Neuroblastoma is a primitive neoplasm of neuroectodermal origin. It is the third most common malignant tumor in the childhood, following lymphoma/leukemia and brain tumors. The peak incidence is 0-4 years (40% in less than 1 year). It is rarely diagnosed prenatally during the 3rd trimester, on ultrasonogram. It occurs anywhere in the sympathoadrenal neuroendocrine system.

    All patients with metastatic (stage 4) disease diagnosed after 18 months of age are in the high-risk category. At the time of diagnosis, the defining characteristics of high-risk neuroblastoma include an age of more than 1 year, metastases, amplification of the MYCN oncogene, and histologic findings.

    Histologically, malignant round cells with or without rosettes and neurofibrillary material are seen. If there are no rosettes or neurofibrillary material, IHC is mandatory. In children more than 5 years, the most important differential diagnoses are Ewing's Sarcoma, lymphoma/leukemia, and rarely small cell osteosarcoma. A panel of antibodies consisting of synaptophysin, chromogranin, CD99, LCA, and Tdt is mandatory. Cells of a neuroblastoma are diffusely positive for synaptophysin and chromogranin, while negative for CD99, LCA, and Tdt [Figure 6].[29] PHOX2 is a useful marker in the diagnosis of peripheral neuroblastic tumors.[30] There is an unequivocal role of genetics in diagnosis and prognosis of neuroblastomas, including N-myc amplification. Lately, there is a focus towards developing risk-based therapies and, ultimately, improving outcome in such cases.[31],[32]
    Figure 6: Case of neuroblastoma metastasizing to the bone (a-d). (a) Cluster of malignant small round cells showing crushing artefact, infiltrating the bone. (H and E, ×400). (c) Diffuse synaptophysin positivity (Diaminobenzidine, ×400). (d) Diffuse chromogranin positivity (Diaminobenzidine, ×400)

    Click here to view


    Primary lymphomas of bone and “look-alikes”

    On radiologic imaging intraosseous lymphomas, Ewing sarcomas and chronic inflammatory lesions have overlapping appearances, including metadiaphyseal involvement, lytic lesions, permeative appearance, and layered/lamellated periosteal reaction.[33] Hitopathologically, the most frequently identified subtype is a diffuse large B cell type of a non-Hodgkin's lymphoma (DLBCL). Considering primary bone lymphomas have relatively better outcomes, as compared with other intraosseous round cell tumors, their differentiation from tumors, such as Ewing sarcomas is important, especially in view of different chemotherapy regimens for treating these two subtypes of RCTs [Figure 7].[6],[34]
    Figure 7: (a) Plain radiograph (post nail fixation) showing a sub trochanteric fracture and a lytic lesion in proximal right femur. (b) Malignant round cell tumor (H and E, ×400). (c) Diffuse CD20 positivity, confirming a Diffuse Large B-cell Non-Hodgkin's lymphoma (Diaminobenzidine, ×400). (d) High Ki67 expression (Diaminobenzidine, ×400) (e) BCL2 positivity (Diaminobenzidine, ×400). Metastatic acute leukemia in parasapinal tissue (D6-D7). (f) Malignant round cell tumor with rosettes (H and E, ×400). Inset: CD99/MIC2 positivity (Diaminobenzidine, ×400). (g) Diffuse Tdt, positivity (Diaminobenzidine, ×400)

    Click here to view


    At the same time, chronic osteomyelitis can mimic intraosseous lymphomas [Figure 8]. Certain features, such as increase in C-reactive protein and a characteristic radiologic feature, namely penumbra sign (a higher signal intensity feature of the thin layer of granulation tissue which lines the abscess cavity on T1-weighted MRI images), is used to differentiate the two lesions.[35] Although not a classic RCT, a plasma cell dyscrasia/tumor can constitute a differential diagnosis of a small RCT, in view of certain overlapping morphological features [Figure 9]a and [Figure 9]b.
    Figure 8: Case of chronic osteomyelitis (a-c). (a) Plain radiograph showing a permeative, 'moth-eaten' lesion involving metadiaphyseal region of humerus with periosteal reaction. (b) Microscopic examination revealing presence of inflammatory cells, including lymphocytes and macrophage, along with necrotic bony fragment. (H and E, ×200). (c) Scattered inflammatory cells, including plasma cells with focal reactive woven bone formation (H and E, ×400)

    Click here to view
    Figure 9: Case of plasma cell tumor, referred as a malignant round cell tumor (a-b). (a) Plasma cells, focally arranged around blood vessel (H and E, ×400). (b) Diffuse CD138/syndecan-1 positivity (Diaminobenzidine, ×400). (c) Case of Langerhans's cell histiocytosis (LCH), in form of a lytic lesion in lower humerus, with periosteal reaction (double contour). (d) Microscopy: Eosinophils, multinucleate giant cells and polygonal cells with intranuclear grooves (H and E, ×400). (e) S100 protein positivity (Diaminobenzidine, ×200). (f) CD1a positivity (Diaminobenzidine, ×200)

    Click here to view


    Langerhans cell histiocytosis (LCH)

    This is an uncommon histiocytic disorder, which accounts for ~0.5-5.4 cases/million persons/year. Although it primarily occurs in the pediatric patients, any age group can be affected. It has a wide spectrum of clinical presentation, ranging from an isolated skin or bone lesion to a life-threatening multisystem disease and the manifestation depends upon the extent of involvement.

    The bone lesions are often asymptomatic and detected incidentally during radiographic investigation for unrelated disorders. Unifocal bone lesions (eosinophilic granuloma) are usually solitary and characteristically affect the calvaria, vertebra, rib, mandible, femur, ilium, and scapula. Bone pain, soft tissue mass, neurologic manifestations because of extension of calvarial lesions into the nervous system, spontaneous long bone fracture, and vertebral collapse with spinal cord compression can occur. Otitis media in temporal and mastoid bone involvement, loose teeth in mandibular lesion, and pituitary dysfunction in sella turcica involvement may be seen. Multifocal lesions might have a protean history depending on the location and degree of bone and adjacent tissue involvement. Diabetes insipidus, exophthalmos, and bony lesion especially in the cranium occur in Hand-—Schüller-Christian disease.

    LCH can involve single system with unifocal or multifocal lesions with i) extraosseous, ii) osseous, iii) skin (seborrheic involvement of scalp, purplish papules on body, red papular rash on groin, abdomen, back, chest, etc.), iv) lymph node, v) hypothalamic/pituitary/central nervous system, or vi) other organs such as thyroid involvement.[36] In a multisystem disease more than or two organs or systems including bone, gastrointestinal tract (liver and spleen), lungs, bone marrow, endocrine and CNS, skin and lymph nodes are affected. Liver and spleen are high-risk organs as any involvement of these organs indicates an unfavorable prognosis. Sclerosing cholangitis is a serious complication. Lungs are more frequently involved in adults. Tachypnea with rib retractions and cystic/nodular pattern are usual clinical signs. Pulmonary involvement is seen in ~25% of children with multisystem disease. Thrombocytopenia and anemia with or without neutropenia are associated with marrow involvement. Patients with hemophagocytosis involving the bone marrow are also at a very high-risk group.

    Radiologically, LCH appears as a lytic lesion, which seems poorly defined in its early phase and relatively well-defined with a sclerotic margin during its late phase of development[37] [Figure 9]c. Microscopically, the lesion contains polymorphous cells with a monoclonal population of CD1a+ histiocytes [Figure 9]d,[Figure 9]e,[Figure 9]f. About 50% cases show activating mutations in proto-oncogene BRAF V600E. Somatic MAP2K1 mutations are present in ~50% of patients, who lack BRAF V600E mutation. Most mutations are “in frame” deletions. Mutations in BRAF and MAP2K1 are mutually exclusive. A debate exists on whether LCH represents a true malignancy. Monoclonality (non-pulmonary lesions), immature appearance of neoplastic cells, cell-cycle dysregulation, telomere shortening, BRAF and MAP2K1 mutation suggest it as a malignancy. Low-risk LCH patients have an excellent prognosis with a long-term survival rate of 99%, whereas the high-risk patients have a survival rate close to 80%. Adult patients usually present with limited skin or bone involvement that can be treated by local therapy, resulting in an overall survival rate of 100%. Smoking cessation can result in the improvement of respiratory symptoms and the spontaneous resolution of pulmonary LCH. Targeted therapy with BRAF inhibitors has been used in select patients with LCH, and the results have been encouraging.[38],[39]


       Conclusion Top


    It is crucial to diagnose individual small cell lesions, especially tumors of the bone, in view of their different treatment regimens. An exact diagnosis required application of ancillary techniques, such as IHC and molecular diagnosis. Morphology remains the cornerstone in the diagnosis and is a guide towards choosing optimal immunohistochemical markers and molecular tests. The value of radiologic correlation in the diagnosis of various bone tumors cannot be overemphasized. At all times, one needs to be aware of “look-alikes,” such as osteomyelitis, which can mimic a Ewing sarcoma. Newer genetic transcripts have been unraveled driving certain undifferentiated round cell/Ewing-like sarcomas. High throughput techniques, such as next-generation sequencing can be utilized in designing and application of panels for RCTs.

    Financial support and sponsorship

    Nil.

    Conflicts of interest

    There are no conflicts of interest.



     
       References Top

    1.
    Li S, Siegal GP. Small cell tumors of bone. Adv Anat Pathol 2010;17:1-11.  Back to cited text no. 1
        
    2.
    Roessner A, Jürgens H. Round cell tumours of bone. Pathol Res Pract 1993;189:111-36.  Back to cited text no. 2
        
    3.
    Llombart-Bosch A, Contesso G, Peydro-Olaya A. Histology, immunohistochemistry, and electron microscopy of small round cell tumors of bone. Semin Diagn Pathol 1996;13:153-70.  Back to cited text no. 3
        
    4.
    Hameed M. Small round cell tumors of bone. Arch Pathol Lab Med 2007;131:192-204.  Back to cited text no. 4
        
    5.
    Seningen J, Inwards CY. Small round cell tumors of bone. Surg Pathol Clin 2012;5:231-56.  Back to cited text no. 5
        
    6.
    Bajpai J, Khanna N, Vora T, Gulia A, Laskar S, Puri A, et al. Analysis of bone and soft-tissue sarcomas registered during the year 2012 at Tata Memorial Hospital, Mumbai, with clinical outcomes. Indian J Cancer 2018;55:37-44.  Back to cited text no. 6
    [PUBMED]  [Full text]  
    7.
    Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics 2016;36:258-78.  Back to cited text no. 7
        
    8.
    Strenger V, Kerbl R, Dornbusch HJ, Ladenstein R, Ambros PF, Ambros IM, et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer 2007;48:504-9.  Back to cited text no. 8
        
    9.
    Rekhi B, Gorad BD, Chinoy RF. Scope of FNAC in diagnosis of soft tissue tumors-A study from a tertiary Cancer Referral Center in India. Cytojournal 2007;4:20.  Back to cited text no. 9
    [PUBMED]  [Full text]  
    10.
    Machado I, Navarro S, Picci P, Llombart-Bosch A. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas. Pathol Res Pract 2016;212:811-6.  Back to cited text no. 10
        
    11.
    Rekhi B, Vogel U, Basak R, Desai SB, Jambhekar NA. Clinicopathological spectrum of 58 Ewing Sarcomas/PNETs, including molecular results with validation of EWSR1 rearrangement by conventional and array FISH technique in certain cases. Pathol Oncol Res 2014;20:503-16.  Back to cited text no. 11
        
    12.
    Hung YP, Fletcher CD, Hornick JL. Evaluation of NKX2-2 expression in round cell sarcomas and other tumors with EWSR1 rearrangement: Imperfect specificity for Ewing sarcoma. Mod Pathol 2016;29:370-80.  Back to cited text no. 12
        
    13.
    Puls F, Niblett A, Marland G, Gaston CL, Douis H, Mangham DC, et al. BCOR-CCNB3 (Ewing-like) sarcoma: A clinicopathologic analysis of 10 cases, in comparison with conventional Ewing sarcoma. Am J Surg Pathol 2014;38:1307-18.  Back to cited text no. 13
        
    14.
    Gambarotti M, Benini S, Gamberi G, Cocchi S, Palmerini E, Sbaraglia M, et al. CIC-DUX4 fusion-positive round-cell sarcomas of soft tissue and bone: A single-institution morphological and molecular analysis of seven cases. Histopathology 2016;69:624-34.  Back to cited text no. 14
        
    15.
    Rekhi B, Basak R, Desai SB, Jambhekar NA. A t (11; 22) (p13; q12) EWS-WT 1 positive desmoplastic small round cell tumor of the maxilla: An unusual case indicating the role of molecular diagnosis in round cell sarcomas. J Postgrad Med 2010;56:201-5.  Back to cited text no. 15
    [PUBMED]  [Full text]  
    16.
    Rekhi B, Ahmed S, Basak R, Qureshi SS, Desai SS, Ramadwar M, et al. Desmoplastic small round cell tumor- Clinicopathological spectrum, including unusual features, and immunohistochemical analysis of 45 tumors diagnosed at a tertiary cancer referral centre, with molecular results (EWS-WT1) in select cases. Pathol Oncol Res 2012;18:917-27.  Back to cited text no. 16
        
    17.
    Fletcher CDM, Bridge JA, Lee J. Undifferentiated/Unclassified sarcomas. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO Classification of Tumours of Soft Tissue and Bone, 4th ed. Lyon: IARC; 2013. p. 236-8.  Back to cited text no. 17
        
    18.
    Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994;331:294-9.  Back to cited text no. 18
        
    19.
    Specht K, Sung YS, Zhang L, Richter GH, Fletcher CD, Antonescu CR. Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas: Further evidence toward distinct pathologic entities. Genes Chromosomes Cancer 2014;53:622-33.  Back to cited text no. 19
        
    20.
    Pierron G, Tirode F, Lucchesi C, Reynaud S, Ballet S, Cohen-Gogo S, et al. Anew subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet 2012;44:461-6.  Back to cited text no. 20
        
    21.
    Italiano A, Sung YS, Zhang L, Singer S, Maki RG, Coindre JM, et al. High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer 2012;51:207-18.  Back to cited text no. 21
        
    22.
    Zoubek A, Pfleiderer C, Salzer-Kuntschik M, Amann G, Windhager R, Fink FM, et al. Variability of EWS chimaeric transcripts in Ewing tumours: A comparison of clinical and molecular data. Br J Cancer 1994;70:908-13.  Back to cited text no. 22
        
    23.
    Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):iv79-95.  Back to cited text no. 23
        
    24.
    Nakashima Y, Unni KK, Shives TC, Swee RG, Dahlin DC. Mesenchymal Chondrosarcoma of bone and soft tissue: A review of 111 cases. Cancer 1986;57:2444-53.  Back to cited text no. 24
        
    25.
    Nakashima Y, de Pinieux G, Ladanyi M. Undifferentiated/Unclassified sarcomas. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO Classification of Tumours of Soft Tissue and Bone, 4th ed. Lyon: IARC; 2013. p. 271-2.  Back to cited text no. 25
        
    26.
    Wehrli BM, Huang W, De Crombrugghe B, Ayala AG, Czerniak B. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Hum Pathol 2003;34:263-9.  Back to cited text no. 26
        
    27.
    Naumann S, Krallman PA, Unni KK, Fidler ME, Neff JR, Bridge JA. Translocation der (13; 21) (q10; q10) in skeletal and extraskeletal mesenchymal Chondrosarcoma. Mod Pathol 2002;15:572-6.  Back to cited text no. 27
        
    28.
    Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer 2012;51:127-39.  Back to cited text no. 28
        
    29.
    Shohet J, Foster J. A review and update on neuroblastoma BMJ 2017;357:j1863.  Back to cited text no. 29
        
    30.
    Bielle F, Fréneaux P, Jeanne-Pasquier C, Maran-Gonzalez A, Rousseau A, Lamant L, et al. PHOX2B immunolabeling: A novel tool for the diagnosis of undifferentiated neuroblastomas among childhood small round blue-cell tumors. Am J Surg Pathol 2012;36:1141-9.  Back to cited text no. 30
        
    31.
    Cheung NK, Dyer MA. Neuroblastoma: Developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013;13:397-411.  Back to cited text no. 31
        
    32.
    Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202-11.  Back to cited text no. 32
        
    33.
    Krishnan A, Shirkhoda A, Tehranzadeh J, Armin AR, Irwin R, Les K. Primary bone lymphoma: Radiographic-MR imaging correlation. Radiographics 2003;23:1371-83; discussion 1384-7.  Back to cited text no. 33
        
    34.
    Heyning FH, Hogendoorn PC, Kramer MH, Hermans J, Kluin-Nelemans JC, Noordijk EM, et al. Primary non-Hodgkin's lymphoma of bone: A clinicopathological investigation of 60 cases. Leukemia 1999;13:2094-8.  Back to cited text no. 34
        
    35.
    Shimose S, Sugita T, Kubo T, Matsuo T, Nobuto H, Ochi M. Differential diagnosis between osteomyelitis and bone tumors. Acta Radiol 2008;49:928-33.  Back to cited text no. 35
        
    36.
    Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016;127:2672-81.  Back to cited text no. 36
        
    37.
    Stull MA, Kransdorf MJ, Devaney KO. Langerhnas cell histiocytosis of bone. Radiographics 1992;12: 801-23.  Back to cited text no. 37
        
    38.
    Bechan GI, Egeler RM, Arceci RJ. Biology of Langerhans cells and Langerhans cell histiocytosis. Int Rev Cytol 2006;254:1-43.  Back to cited text no. 38
        
    39.
    Alayed K, Medeiros LJ, Patel KP, Zuo Z, Li S, Verma S, et al. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: A study of 50 cases. Hum Pathol 2016;52:61-7.  Back to cited text no. 39
        

    Top
    Correspondence Address:
    Bharat Rekhi
    Room Number 818, Department of Surgical Pathology, 8th Floor, Annex Building, Tata Memorial Hospital, Dr E.B. Road, Parel, Mumbai - 400 012, Maharashtra
    India
    Login to access the Email id

    Source of Support: None, Conflict of Interest: None


    DOI: 10.4103/IJPM.IJPM_675_18

    Rights and Permissions


        Figures

      [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8], [Figure 9]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
   Conclusion
    References
    Article Figures

 Article Access Statistics
    Viewed356    
    Printed7    
    Emailed0    
    PDF Downloaded95    
    Comments [Add]    

Recommend this journal